Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial
In CKD and type 2 diabetes, canagliflozin reduces insulin use with consistent effects regardless of baseline kidney function. This supports the use of canagliflozin in people with CKD, not only for end-organ protection, but also to improve glycaemic control and reduce exposure to insulin and its associated adverse effects.
Authors
- Brendon Lange Neuen (ORCID: https://orcid.org/0000-0001-9276-8380)
- Carol A. Pollock (ORCID: https://orcid.org/0000-0001-7167-6495)
- Vlado Perkovic (ORCID: https://orcid.org/0000-0002-4257-7620)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Clare Arnott (ORCID: https://orcid.org/0000-0001-9370-9913)
- Emily K. Yeung (ORCID: https://orcid.org/0000-0002-1244-1044)
- Lauren Houston (ORCID: https://orcid.org/0000-0003-0825-0373)
- Luke Buizen
- Lauren Heath (ORCID: https://orcid.org/0000-0002-0255-3501)
- Sradha S. Kotwal (ORCID: https://orcid.org/0000-0002-3294-4087)
- Meg Jardine (ORCID: https://orcid.org/0000-0002-0160-2375)
- Bryony Beal (ORCID: https://orcid.org/0000-0002-5697-4563)
Institutions
- The University of Sydney (AU)
- New South Wales Department of Health (AU)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Royal Prince Alfred Hospital (AU)
- Royal North Shore Hospital (AU)
- Concord Repatriation General Hospital (AU)
- Toronto General Hospital (CA)
- UNSW Sydney (AU)
- Prince of Wales Hospital (AU)
- The George Institute for Global Health (AU)
- National Health and Medical Research Council (AU)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1093/ndt/gfaf044
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00